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Review Article

Complete versus culprit only revascularization in ST-elevation
myocardial infarction—a perspective on recent trials and
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Abstract: The presence of multivessel coronary artery disease (CAD) is strongly associated with higher
30-day mortality, reduced myocardial reperfusion success, reinfarction, and occurrence of major adverse
cardiac events (MACE) at 1 year compared with single-vessel CAD. Despite higher morbidity and mortality
in patients with ST-elevation myocardial infarction (STEMI) and coexistent multivessel CAD, major
guidelines recommended against percutaneous coronary intervention (PCI) on non-culprit lesions at the time
of primary PCI in patients with STEMI who are hemodynamically stable. The presence of multivessel CAD
often poses a therapeutic dilemma for interventional cardiologists. A few larger scale randomized controlled
trials (RCTs) and meta-analyses have been conducted. The conclusions regarding multivessel PCI generally
trend towards lower risk of MACE, repeat revascularization, with similar risks of recurrent myocardial
infarction (MI) and mortality. However, none of the RCTs were adequately powered for hard outcomes of
death and MI.
Keywords: Coronary artery disease (CAD); ST-elevation myocardial infarction (STEMI); percutaneous coronary
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Introduction
There has been a recent decline in the incidence of STelevation myocardial infarction (STEMI) (1,2). However,
multivessel (MV) coronary artery disease (CAD) is
frequently encountered (45–60%) in patients undergoing
primary percutaneous coronary intervention (PCI) for
STEMI (3-6). In contrast to stable lesions in stable
CAD, non-culprit lesions in patients with acute coronary
syndrome (ACS) tend to have more diffuse CAD and lesscalcified plagues (7,8). The plaques in ACS patients are also
more vulnerable, with large amount of necrotic core (7) and
thin-cap fibroatheromas, consistent with high-risk features.
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This could potentially lead to development of future
major adverse cardiovascular events (9). The presence of
MV-CAD is strongly associated with higher 30-day
mortality, reduced myocardial reperfusion success,
reinfarction, and occurrence of major adverse cardiac events
(MACE) at 1-year compared with single vessel CAD (4-6).
Despite higher morbidity and mortality in patients with
STEMI and coexistent MV CAD, guidelines published
by the American College of Cardiology/American Heart
Association (ACC/AHA) in 2013 recommended against
PCI on non-culprit lesions at the time of primary PCI in
patients with STEMI who are hemodynamically stable (10).
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The 2014 European Society of Cardiology/European
Association of Cardio-Thoracic Surgery guidelines also
similarly recommend systematic primary PCI of the
culprit vessel and advocate for additional non-culprit vessel
revascularization only in patients with cardiogenic shock,
especially when the lesions are multiple, unstable, or with
critical stenosis, and if persistent ischemia exists after PCI of
the culprit lesion (11). However, only 25% of patients with
cardiogenic shock and MV CAD receive MV PCI during
STEMI (12).
The recommendations against PCI of non-culprit
lesions were largely driven by results of nonrandomized
observational studies with conflicting results. The
rationale behind not recommending routine complete
revascularization was increased in-hospital mortality,
contrast-induced nephropathy (CIN), and MACEs
associated with MV-PCI during the index procedure (13-17).
Small randomized controlled trials (RCTs) reported
potential safety and benefits of complete and staged
revascularization in reducing long-term MACE (18,19).
In multicenter randomized Hepacoat for Culprit or
Multivessel Stenting for Acute Myocardial Infarction
(HELP-AMI) study (19), with a total of 69 patients
(17 patients in culprit-only PCI group and 52 patients
in multivessel PCI group), the investigators found that
MVPCI at the time of index procedure was not associated
with increase in in-hospital adverse events and had similar
overall healthcare cost as compared to culprit-only PCI (19).
In the Primary Angioplasty in Patients Transferred From
General Community Hospitals to Specialized PTCA Units
With or Without Emergency Thrombolysis (PRAGUE-13)
trial (20), the authors compared staged MV-PCI (n=106)
with culprit-only PCI (n=108) in STEMI patients with
MV-CAD. This study found no difference in the long
term development of composite primary end-point of allcause mortality, non-fatal MI, and stroke between the two
revascularization strategies (20).
The presence of MV-CAD often poses a therapeutic
dilemma for interventional cardiologists as there are
multiple options in patients with MV-CAD and insufficient
data regarding benefit in reducing end-point such as
mortality and MI. These options are culprit artery-only
primary PCI, complete revascularization (MV-PCI) at the
time of index procedure, or staged revascularization (primary
PCI followed by ischemia or symptom guided PCI of the
non-culprit lesion within days or weeks after primary PCI).
In this review, we will discuss the recently published RCTs
(Table S1) designed to investigate optimal revascularization
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strategy in managing STEMI patients with MV-CAD and
their impact on current clinical practice and guidelines.
RCTs (Table S1)
Politi et al. (18)
Out of a total of 263 consecutive patients with STEMI
and MV-CAD, 214 patients were randomly assigned to
culprit-only PCI (n=81), complete revascularization during
the index procedure (n=65), and staged revascularization
performed approximately two months after the index
procedure (n=65) (18). Patients with cardiogenic shock at
presentation (systolic blood pressure ≤90 mmHg despite
drug therapy), left main coronary disease (≥50% diameter
stenosis), previous coronary artery bypass graft (CABG)
surgery, severe valvular heart disease and unsuccessful
revascularization were excluded from the study. Patients
were followed for a mean duration of 2.5±1.4 years (18).
The investigators found that culprit-only revascularization
had a higher rate of at least one MACE (50%), compared
to staged revascularization (20%) and immediate complete
revascularization (23%) at a mean follow-up of 2.5 years
(P<0.001). The staged and immediate complete
revascularization group had a 63% (P=0.003) and a 60%
lower risk of MACE (P=0.002), respectively. This result
was mainly driven by a lower incidence of in-hospital death,
re-PCI, and rehospitalization. Kaplan-Meier
analysis showed a worse outcome in the culprit-only
revascularization group (worse survival-free of MACE,
survival-free of re-PCI), but no significant difference in
outcomes between the staged and immediate complete
revascularization groups. There were no significant
differences in CIN incidence and length of hospital stay
between the 3 study groups (18). This study suffered
from a small sample size and utilization of unrestricted
randomization instead of block randomization leading to
imbalances in the treatment arms (25). It was also unclear
whether patients in the culprit-only revascularization
group had any non-invasive ischemia testing within
2.5 years, which could qualify these patients for staged
revascularization. This could potentially explain the higher
incidence of repeat revascularization and re-hospitalization
in the culprit-only revascularization group (26).
PRAMI (21)
In the Preventive Angioplasty in Acute Myocardial
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Infarction (PRAMI) trial, a total of 465 patients were
randomly assigned to culprit only revascularization
(n=231) and complete revascularization during the index
procedure (n=234) (21). Staged revascularization in the
asymptomatic patients was discouraged. Once the infarctrelated artery was treated, the patients were included in the
trial if they had a PCI-amenable ≥50% stenosis in one or
more non-infarct-related coronary arteries. Patients who
were in cardiogenic shock, unable to provide consent, had
undergone previous CABG, had a non-infarct stenosis of
50% or more in the left main stem or the ostia of both the
left anterior descending and circumflex arteries, or if the
only non-culprit stenosis was a chronic total occlusion were
excluded. Patients were followed for a mean follow-up
duration of 23 months (21).
This study reported a 65% reduction in the primary
endpoint in the complete revascularization group compared
to the culprit-only revascularization group. Complete
revascularization group also had a significantly lower risk
for repeat revascularization and composite of death from
cardiac causes or non-fatal MI. The Kaplan-Meier analysis
showed that the risk reduction benefit was apparent within 6
months after the procedure (21). This study, however, failed
to address the question whether similar benefit could be
obtained when PCI was performed as a delayed procedure
(staged revascularization) (27).
DANAMI-3 PRIMULTI (22)
In The Third Danish Study of Optimal Acute Treatment of
Patients with STEMI: Primary PCI in Multivessel Disease
(DANAMI-3 PRIMULTI), 627 patients were randomly
allocated to complete revascularization (n=314) and culprit
only revascularization (n=313) (22). After successful PCI of
the culprit lesion, patients with an angiographic diameter
stenosis of greater than 50% in one or more non-infarct
related arteries were included in the trial. Patients were
excluded if they were intolerant of contrast media or of
relevant anticoagulant or antithrombotic drugs, unconscious
or suffered from cardiogenic shock, stent thrombosis, met
indication for CABG, or had an increased bleeding risk.
Complete revascularization was performed in a staged
manner 2 days after the index procedure during the index
hospitalization, and was guided by fractional flow reserve
(FFR), if appropriate. In non-culprit lesions with a greater
than 50% diameter stenosis, FFR values were calculated
(FFR ≤0.8 considered significant) (22).
One-third of patients allocated to the complete
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revascularization group did not receive PCI as they had
FFR values >0.80. The investigators found that complete
revascularization was associated with a 44% reduction in
the incidence of the composite primary endpoint, which
was largely driven by a 69% reduction of ischemia-driven
revascularization of the non-infarct related arteries. There
were no significant differences in the all-cause mortality and
non-fatal reinfarction rates between the 2 groups. There
were also no significant differences in cardiovascular death
or non-fatal MI, although complete revascularization was
significantly associated with a lower need for both urgent
and non-urgent PCI of the lesions in the non-culprit
arteries (22). This trial failed to show an impact on hard
outcomes (such as death and MI due to lack of power). The
optimal timing of non-infarct related artery PCI (index
admission versus staged outpatient procedure) remains a
debate (28,29).
CvLPRIT (23)
The Complete versus Lesion-only Primary PCI (CvLPRIT)
trial randomized 296 STEMI patients and MVCAD to culpritonly (n=146) and complete (n=150) revascularization (23).
Exclusion criteria were an age <18 years, clear indication
for, or contraindication to, MV primary PCI according to
operator judgement, prior MI, patients with prior CABG,
cardiogenic shock, ventricular septal rupture or moderate/
severe mitral regurgitation, chronic kidney disease,
suspected or confirmed thrombosis of a previously stented
artery, and when the only significant non-infarct-related
lesion is a chronic total occlusion (23).
Complete revascularization was done either during
the index procedure or the index hospitalization (staged
revascularization). The primary endpoint of this study
was MACE, which was a composite of all-cause mortality,
recurrent MI, heart failure, and ischemic-driven
revascularization by PCI or CABG within 12 months.
This study reported a 55% reduction of MACE in the
patients undergoing complete revascularization compared
to the culprit-only revascularization. The occurrence
of individual components of the primary endpoint was
insignificantly lower in the complete revascularization
group. Sixty-four percent of patients underwent complete
revascularization during the index procedure, while the
others had a staged revascularization. Patients receiving
complete revascularization during the index procedure had
a trend towards a reduced prevalence of MACE compared
to staged revascularization. There were no differences in the
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occurrence of adverse events, such as stroke, major bleeding
(all non-CABG related), or CIN between the infarct-related
revascularization and complete revascularization groups (23).
The study was not powered to assess the individual
components of the primary composite endpoint (30). The
study did not include intravascular ultrasound or FFR for
the non-infarct-related lesion characterization anatomically
or physiologically, respectively.
Compare-Acute Trial (24)
The Comparison Between FFR Guided Revascularization
Versus Conventional Strategy in Acute STEMI Patients
With MVD (COMPARE-ACUTE) Trial enrolled 885
STEMI patients with non-infarct-related coronary stenosis of
50% or more (24). Patients were randomly assigned in a ratio
of 1:2 to FFR-guided complete revascularization (n=295) and
culprit-only revascularization (n=590). Exclusion criteria
were left main CAD, chronic total occlusion, severe stenosis
with a Thrombolysis in Myocardial Infarction (TIMI)
flow grade of 2 or less in the non-infarct-related coronary
artery, a suboptimal result or complication after treatment
of infarct-related artery, severe valve dysfunction, and Killip
class III or IV. Complete revascularization was performed
in lesions with FFR ≤0.80, preferably within 72 hours
(complete PCI was performed during index procedure
in 83.4 % patients). Primary end-point of the study was
the composite of all-cause mortality, non-fatal MI, any
revascularization, and cerebrovascular events (MACCE) at
12 months (24).
As the FFR measurement was performed in both groups,
this study showed that approximately half of the patients
had one or more non-infarct-related artery lesions with an
FFR of 0.80 or less. The investigators found that complete
revascularization group had significantly lower rate of
MACCE compared to culprit-only revascularization group
which seems to be driven mainly by the decreased need for
revascularization. The other components of primary endpoint (all-cause mortality, MI, and cerebrovascular event)
did not differ statistically between both groups (24).
Although this study showed that FFR-guided
revascularization could be safely performed in acute setting
of STEMI and cost-effective, it is questionable whether
the result of trial can also be applied to much sicker patient
populations. In addition, there is a potential bias as the
angiographic result of culprit-only revascularization group
was made known to patients and cardiologist, which could
contribute to higher subsequent revascularization among
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that group (31).
Meta-analyses
Spencer et al. (32) in their systematic review, which included five
RCTs [RCT by Politi et al. (18), HELP-AMI (19), PRAMI (21),
DANAMI-3 PRIMULTI (22), and CvLPRIT (23)] enrolling
1,606 patients, concluded that complete revascularization
was associated with significant reduction in the risk of repeat
revascularization, non-fatal MI, cardiovascular mortality
compared to culprit-only revascularization. However,
the investigators did not find any difference in the total
mortality between the two groups (32). A separate metaanalysis which recruited nine RCTs with total 2,176 patients,
agreed that complete revascularization strategy was overall
better in lowering risk of MACE, repeat revascularization,
cardiovascular mortality, but found no difference in
mortality or recurrent MI. The investigators also compared
the three revascularization strategies (culprit-only,
complete revascularization at index procedure, and complete
revascularization as staged procedure) and showed that
complete revascularization during index procedure seemed
to be more superior than two other strategies (33). However,
more recent meta-analysis, conducted by Fan et al. (34),
concluded the opposite: complete revascularization as
staged procedure deemed better than immediate complete
revascularization or culprit-only revascularization in
reducing all-cause mortality (34).
Numerous other meta-analyses have been conducted and
published since the RCTs (Table 1). They have discordant
results, which was largely driven by the inclusion of different
variety of trials to conduct the meta-analyses and by the fact
that none of the RCTs were adequately powered for the hard
outcomes of death and MI. Overall, MV-PCI seems to be
associated with lower risk of MACE, repeat revascularization,
but with a similar risks of recurrent MI and mortality
compared to culprit-only revascularization (32-44).
Timing of revascularization
Timing of revascularization remains an area of intense
controversy and debate. Wang et al. (43) performed a
subgroup analysis in their meta-analysis, comparing
outcomes in complete revascularization at the time of the
index procedure (immediate complete revascularization) and
staged revascularization with culprit-only revascularization.
Immediate complete revascularization had a significantly
lower incidence of MACE, all-cause death and/or MI, non-
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4 RCTs, 14 observational 40, 180
studies

5 RCTs

8 RCTs

13 prospective;
19 retrospective studies

7 RCTs

9 RCTs

7 RCTs

8 RCTs

9 RCTs

Bittl JA (38), 2015

Spencer FA (32), 2015

Bajaj NS (39), 2015

Tarantini G (40), 2016

Villablanca PA (41), 2016

Shah R (33), 2016

Bainey KR (42), 2016

Wang CH (43), 2017

Fan ZG (34), 2017
–

789

980

939

940

940

42, 112

919

775

666

478

Immediate complete:
347; staged: 562

975

1,080

1,065

1,236

1,066

Immediate complete:
8,138; staged: 3,898

1,054

793

7,588

637

566

646

Lower risk of mortality and MACE with staged PCI. No difference in
MI and revascularization

Lower risk of MACE, long-term mortality, reinfarction, and repeat
revascularization in complete revascularization group

Lower risk of MACE and repeat revascularization in complete
revascularization group. Mortality and MI are similar

Similar risk of death and MI

Lower risk of MACE, revascularization, CV mortality in complete
revascularization group. MI and all-cause mortality were similar

Lower risk of MACE, CV mortality, repeat revascularization in
complete revascularization group. All-cause mortality and MI were
similar

Lower short and long term mortality in staged revascularization
compared to culprit-only and immediate complete revascularization

Lower risk of MACE, revascularization, repeat PCI in complete
revascularization group. All-cause mortality, reinfarction were similar

Lower risk of repeat revascularization, recurrent non-fatal MI, CV
mortality in complete revascularization group. Total mortality was
similar

Similar mortality risk

Lower risk of MACE, recurrent MI, repeat revascularization in
complete revascularization group. All-cause mortality, CV mortality
were similar

Lower all-cause mortality, CV mortality, recurrent MI, repeat
revascularization in complete revascularization group

Lower risk of MACE, mortality, repeat revascularization in complete
revascularization group. Non-fatal MI was similar

Results

RCT, randomized controlled trial; MACE, major adverse cardiac events; MI, myocardial infarction; CV, cardiovascular; PCI, percutaneous coronary intervention.

4 RCTs
6 non-RCTs

7 RCTs

Kowalewski M (37), 2015

Li Z (44), 2017

4 RCTs

El-Hayek GE (36), 2015

519

5 RCTs

Bangalore (35), 2015

Culprit-only
Complete
revascularization (N) revascularization (N)

Studies included

First author,
year published

Table 1 Meta-analyses of complete vs. culprit only revascularization
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fatal MI, and repeat revascularization when compared to
the culprit-only revascularization. Staged revascularization
reduced only the incidence of MACE. This showed that
immediate complete revascularization might be more
superior compared to staged revascularization. This finding
seems to be opposite of what was found in other metaanalyses (40,44) and the few observational studies (45,46).
Kornowski et al. (45) performed a post-hoc analysis of the
Harmonizing Outcomes with Revascularization and Stents
in Acute Myocardial Infarction (HORIZONS-AMI) trial.
This was a RCT originally designed to compare bivalirudin
versus heparin plus a glycoprotein IIb/IIIa inhibitor and
paclitaxel-eluting stents versus bare-metal stents in patients
undergoing primary PCI for STEMI. A total of 668 STEMI
patients were identified to have undergone MV-PCI
in the original trial. Two hundred and seventy-five patients
underwent MV-PCI during the index procedure, whereas
393 patients underwent staged revascularization (6–50 days
after primary PCI). This study showed that MV-PCI during
index procedure was associated with an increased all-cause
mortality [hazard ratio (HR) 4.1, 95% CI: 1.93–8.86,
P<0.0001] and cardiovascular mortality (HR 3.41, 95% CI:
1.35–7.27, P=0.005) compared to the staged MV-PCI (45).
Similarly, a meta-analysis by Tarantini et al. (40) revealed
that staged revascularization was associated with short-and
long-term survival compared with both immediate complete
revascularization and culprit-only revascularization. In
separate meta-analysis by Li et al. (44) which compared staged
revascularization and immediate complete revascularization
head-to-head, the former seemed to be a better strategy.
Iqbal et al. (46) performed an observational study which
compared the 3 revascularization strategies (immediate
complete revascularization, staged revascularization, and
culprit-only revascularization) in 6,503 STEMI patients
with MV-CAD. The primary outcome was all-cause
mortality and repeat revascularization at 2 years. The
investigators found that staged revascularization was
associated with a lower mortality at 1 year and 2 years when
compared with either immediate complete revascularization
or culprit-only revascularization. This study also showed
lower repeat revascularization rates at 30 days, 1 year, and
2 years when compared with culprit-only revascularization.
The authors concluded that staged PCI of the non-culprit
vessel (if indicated) may yield better results, and MV-PCI at
time of index procedure may be considered in patients with
non-culprit LAD disease (46).
Of the RCTs discussed in detail above, Politi et al. (18)
was the only trial that included both staged and immediate
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complete revascularization and analyzed them separately.
PRAMI (21) was the only trial that specifically compared
MV-PCI at time of index procedure to culprit-only
revascularization. DANAMI-3 PRIMULTI (22) compared
only staged revascularization to culprit only-revascularization.
CvLPRIT (23) and Compare-Acute Trial (24) combined
both immediate and staged revascularization (mentioned
as complete revascularization) at time of data analysis.
The variability on how the trials were conducted leads
to uncertainty and confusion on when and how complete
revascularization should be performed. This warrants a
larger scale RCT to confirm the present findings, as well
as to determine the impact of such intervention on hard
endpoints such as mortality or MI.
A large, ongoing, Complete vs. Culprit-only
Revascularization to Treat Multivessel Disease After Primary
PCI for STEMI (COMPLETE) trial (ClinicalTrials.
gov. Identifier: NCT01740479) was designed to enroll
3,900 STEMI patients with MV-CAD randomly assigning
them to receive either staged revascularization or culpritonly revascularization, on top of optimal medical therapy
(including low dose aspirin and ticagrelor). This trial was
started in December, 2012, and is estimated to be completed
in December, 2018. The primary outcome of this study is a
composite of cardiovascular death or new MI over a follow-up
of approximately 4 years. The secondary outcome is a
composite of cardiovascular death, new MI, ischemia-driven
revascularization or hospitalization for unstable angina or
heart failure. The results of this trial are expected to provide
a better understanding of whether staged revascularization
is better than culprit-only revascularization in STEMI
patients with MV-CAD undergoing primary PCI.
2015 ACC/AHA focused update and 2016 ACC/
AHA appropriate use criteria
The publication of larger scale RCTs has prompted
ACC/AHA to change the recommendation for complete
revascularization to class IIb in the recent 2015 ACC/
AHA/SCAI Focused Update on Primary Percutaneous
Intervention for Patients with ST-Elevation Myocardial
Infarction (47). These guidelines specifically mention
that PCI of a non-infarct artery may be considered in
selected patients with STEMI and MV-CAD who are
hemodynamically stable, either at the time of primary PCI
or as a planned staged procedure (47).
The 2016 Appropriate Use Criteria for Coronary
Revascularization in Patients with ACS also addressed the
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issue on how to treat MV-CAD in STEMI patients (48).
Multivessel revascularization at the time of the index
procedure with PCI or CABG was deemed appropriate
in patient with cardiogenic shock persisting after PCI of
the presumed culprit artery. Whereas revascularization of
non-culprit artery during initial hospitalization (as staged
procedure) was considered appropriate in MV-CAD patients
with spontaneous or easily provoked symptoms of myocardial
ischemia, asymptomatic patients with findings of ischemia
on non-invasive testing, and asymptomatic patients with an
intermediate (50–70%) stenosis and a FFR ≤0.8 (48).
Conclusions
In conclusion, it seems prudent to consider MV-PCI at the
time of the index procedure in patients with cardiogenic
shock, severe left ventricular dysfunction and hemodynamic
instability. MV-PCI at the time of the index procedure can
also be considered in patients with angiographically critical
atherosclerotic plaques (high thrombus burden, ulcerated,
TIMI flow <3, angiographic stenosis >95%) especially in
the left anterior descending artery. MV-PCI at the index
procedure may be considered in situations where it is difficult
to determine the culprit lesion (for example coexistent
left circumflex and right coronary artery critical lesions in
patients with inferior wall ACS). In patients who are older,
have chronic comorbid conditions such as diabetes or chronic
kidney disease, a staged approach for non-culprit lesions
may be preferred to prevent acute kidney injury. Timing of
the staged procedure is debatable (same admission versus
outpatient) and relies on the clinical scenario, ongoing
symptoms and patient-physician preference after a riskbenefit discussion. Noninvasive or invasive testing (FFR) may
be considered in the non-acute staged setting, as appropriate.
Until more data are available, an individualized approach
should be adopted after careful evaluation of the lesion
severity, hemodynamics, underlying comorbidities, vascular
access, physician comfort, and cardiac catheterization
laboratory ancillary staff availability (day versus night).
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Supplementary
Table S1 RCTs of complete vs. culprit only revascularization
Total of
patients

Number of patient in
multivessel PCI

Number of patient
in culprit-only PCI

Lesion criteria
(% stenosis)

Timing for non-culprit lesion
revascularization

Duration of
follow up

Culprit only revascularization
vs. staged revascularization
vs. complete
revascularization

214

Staged: 65 patients
(30.4%); complete:
65 patients (30.4%)

84 (39.2%)

>70% of two or more coronary
arteries or their major branches
by visual estimation

During index procedure (30.4%
of patients) or staged (30.4% of
patients), staged procedure done
56.8±12.9 days after the index
procedure

April 2008–January
2013

Culprit only revascularization
vs. complete
revascularization

465

234

231

>50% stenosis

Danami-3
PRIMULTI (22)

March 2011–Feb 2014

Culprit only revascularization
vs. ffr-guided complete
revascularization (staged)

627

314

313

CvLPRIT (23)

May 2011–May 2014

Complete vs. culprit-only
revascularization

296

150

CompareAcute Trial (24)

July 2011–October
2015

Culprit-only revascularization
vs. ffr-guided complete
revascularization

885

295

RCT

Timing of study

Study group

Politi et al. (18)

Jan 2003–Dec 2007

PRAMI (21)

Primary end-point

Secondary end-point

Study results

2.5±1.4 years

Major adverse cardiac event
(cardiac or non-cardiac death,
inhospital death, re-infarction,
re-hospitalization for ACS and
repeat coronary revascularization)

–

63% lower risk of MACE in staged
revascularization group, 60% lower risk of
MACE in complete revascularization group
compared to culprit-only revascularization
group, higher risk of repeat unplanned
revascularization, rehospitalization
and in-hospital death in culprit-only
revascularization group

During index procedure

23 months

Composite of death from cardiac
causes, non-fatal MI, refractory
angina

Death from non-cardiac cause, repeat
revascularization procedures (PCI or CABG)

65% reduction in primary outcome, no
significant difference in death (either from
cardiac or non-cardiac cause)

>50% in one or more non-infarct
related arteries

2 days after index procedure before
discharge

27 (range
12–44) months

Composite of all-cause mortality,
reinfarction, or ischemia-driven
revascularizations in non-infarct
related arteries

Components of the primary end-point,
occurrence of cardiac death, urgent and nonurgent PCI of lesions in non-infarct related
arteries

44% reduction in primary endpoint, largely
driven by 69% reduction in all-cause
mortality

146

>70% diameter stenosis in one
plane or >50% in 2 planes

During index procedure or index
admission

12 months

MACE (all-cause mortality,
recurrent MI, HF, ischemic-driven
revascularization by PCI/CABG)

Cardiovascular death, individual component of
the primary endpoint, and the safety endpoints
of stroke, major bleeding, and CIN

55% lower risk of MACE in complete
revascularization group

590

>50% plus history of angina or
evidence of ischemia; or >70%
on angiography; with FFR ≤0.80

During index hospitalization (83.4%
of patients had complete PCI during
index procedure)

36 months

Composite of all-cause
mortality, non-fatal MI,
any revascularization, and
cerebrovascular events at 12
months

Primary end-point at 24 and 36 months; each
components of primary end-point; composite
of all-cause mortality and MI; composite of
cardiac death, MI, any revascularization, stroke,
and major bleeding; composite of heart failure
hospitalization and unstable angina pectoris;
stent thrombosis; treatment cost; bleeding at
48 hours and 12 months

65% lower risk of primary end-point,
largely drive by 68% reduction in
revascularization

ACS, acute coronary syndrome; RCT, randomized controlled trial; MACE, major adverse cardiac events; MI, myocardial infarction; CV, cardiovascular; PCI, percutaneous coronary intervention; HF, heart failure; CIN, contrast-induced nephropathy; CABG, coronary artery bypass grafting.

